Abstract Purpose of Review The outbreak of the novel coronavirus disease 2019 (COVID-
19) has emerged to be the biggest global health threat worldwide, which has now infected …

Immunotherapy is associated with durable clinical benefit in patients with melanoma. The
goal of this article is to provide evidence‑based consensus recommendations for the use of …

Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and
although the incidence of primary melanoma continues to rise, the mortality from metastatic …

Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …

Background In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint
pathways by nivolumab and ipilimumab was associated with a high rate of objective …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

PURPOSE Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic
melanoma and on this basis has been evaluated as an adjuvant therapy following surgery …

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of
immune-based therapies, including the widely used class of agents known as immune …

Background Brain metastases are a common cause of disabling neurologic complications
and death in patients with metastatic melanoma. Previous studies of nivolumab combined …

Background Results from phase 2 and 3 trials in patients with advanced melanoma have
shown significant improvements in the proportion of patients achieving an objective …